Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D) Meeting Abstract
| Authors: | Schuler, M. H.; Ascierto, P. A.; De Vos, F. Y. F. L.; Postow, M. A.; Van Herpen, C. M. L.; Carlin, M. S.; Sosman, J. A.; Berking, C.; Long, G. V.; Weise, A.; Gutzmer, R.; Kaatz, M.; McArthur, G. A.; Schwartz, G.; Daud, A.; Maharry, K.; Yerramilli-Rao, P.; Zimmer, L.; Bozon, V.; Amaria, R. N. |
| Abstract Title: | Phase 1b/2 trial of ribociclib plus binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D) |
| Meeting Title: | 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 35 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2017 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2017-05-20 |
| Start Page: | 480s |
| Language: | English |
| ACCESSION: | WOS:000411932203162 |
| DOI: | 10.1200/JCO.2017.35.15_suppl.9519 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 9519 -- Source: Wos |
